Clinical trials

Analysis and Comment (6)

Svtj9mzb-1369999362
Tamiflu was stockpiled amid flu outbreaks and scares. Rui Vieira/PA

Tamiflu cost us £424m yet we still don’t know much about it

By Tom Jefferson, Cochrane Collaboration

Are you worried about how decisions involving public money are made? You should be. Last week, the National Audit Office disclosed that the Department of Health spent £424 million on the anti-flu drug…
Cr3nhvgx-1358213106
Non-publication of clinical trial data is a waste of research resources, among other things. Esther Dyson

Register all trials, report all results – it’s long overdue

By Paul Glasziou

If researchers go to the effort of getting funds, recruiting patients, and following them up, you would think that they would be keen to publish the results. So it’s surprising that our best estimates…
Q5ggh5c7-1340257629
Post-marketing studies are often used as ploys to get doctors in the habit of prescribing expensive new medicines. Flickr / Nestle

How Big Pharma opens the market to new expensive drugs

By Agnes Vitry, University of South Australia

New medicines are often marketed on the basis of clinical trials of limited size and duration. So clinical studies of a medicine after it has reached the market (post-marketing studies) can be a useful…
Zv8r9x76-1333604901
AAP/Tracey Nearmy

Why data from published trials should be made public

By Ian Haines, Monash University

TRANSPARENCY AND MEDICINE – A series examining issues from ethics to the evidence in evidence-based medicine, the influence of medical journals to the role of Big Pharma in our present and future health…

Research and News (4)

Research Briefs (2)

Participants (23)